Last reviewed · How we verify
Sovaldi
Sovaldi is a Small molecule drug developed by Genuine Research Center, Egypt. It is currently FDA-approved for Chronic hepatitis C, Compensated cirrhosis, Decompensated cirrhosis of liver. Also known as: Sofosbuvir, GS-7977.
At a glance
| Generic name | Sovaldi |
|---|---|
| Also known as | Sofosbuvir, GS-7977 |
| Sponsor | Genuine Research Center, Egypt |
| Target | Cereblon isoform 4, Genome polyprotein, NS5 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Chronic hepatitis C
- Compensated cirrhosis
- Decompensated cirrhosis of liver
Common side effects
- Fatigue
- Headache
- Nausea
- Insomnia
- Anemia
Serious adverse events
- Pancytopenia
- Severe depression
- Suicidal ideation
- Suicide
- Bilirubin elevation (>2.5×ULN)
- Creatine kinase elevation (≥10×ULN)
- Lipase elevation (>3×ULN)
- Neutropenia
Key clinical trials
- People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (PHASE4)
- A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients (PHASE2)
- Implementing Low-Barrier HCV Treatment in a Jail Setting (PHASE4)
- Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients (NA)
- Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (PHASE4)
- Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (PHASE2)
- C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV (PHASE3)
- SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sovaldi CI brief — competitive landscape report
- Sovaldi updates RSS · CI watch RSS
- Genuine Research Center, Egypt portfolio CI
Frequently asked questions about Sovaldi
What is Sovaldi?
Sovaldi is a Small molecule drug developed by Genuine Research Center, Egypt, indicated for Chronic hepatitis C, Compensated cirrhosis, Decompensated cirrhosis of liver.
What is Sovaldi used for?
Sovaldi is indicated for Chronic hepatitis C, Compensated cirrhosis, Decompensated cirrhosis of liver.
Who makes Sovaldi?
Sovaldi is developed and marketed by Genuine Research Center, Egypt (see full Genuine Research Center, Egypt pipeline at /company/genuine-research-center-egypt).
Is Sovaldi also known as anything else?
Sovaldi is also known as Sofosbuvir, GS-7977.
What development phase is Sovaldi in?
Sovaldi is FDA-approved (marketed).
What are the side effects of Sovaldi?
Common side effects of Sovaldi include Fatigue, Headache, Nausea, Insomnia, Anemia. Serious adverse events: Pancytopenia, Severe depression, Suicidal ideation, Suicide.
What does Sovaldi target?
Sovaldi targets Cereblon isoform 4, Genome polyprotein, NS5.
Related
- Target: All drugs targeting Cereblon isoform 4, Genome polyprotein, NS5
- Manufacturer: Genuine Research Center, Egypt — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Chronic hepatitis C
- Indication: Drugs for Compensated cirrhosis
- Indication: Drugs for Decompensated cirrhosis of liver
- Also known as: Sofosbuvir, GS-7977